RU96122169A - Нон-сплайсинговые варианты gp350/220 - Google Patents
Нон-сплайсинговые варианты gp350/220Info
- Publication number
- RU96122169A RU96122169A RU96122169/13A RU96122169A RU96122169A RU 96122169 A RU96122169 A RU 96122169A RU 96122169/13 A RU96122169/13 A RU 96122169/13A RU 96122169 A RU96122169 A RU 96122169A RU 96122169 A RU96122169 A RU 96122169A
- Authority
- RU
- Russia
- Prior art keywords
- homogeneous
- protein
- amino acids
- dna sequence
- nucleotide
- Prior art date
Links
- 150000001413 amino acids Chemical class 0.000 claims 8
- 239000002773 nucleotide Substances 0.000 claims 8
- 125000003729 nucleotide group Chemical group 0.000 claims 8
- 102000004169 proteins and genes Human genes 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 1
Claims (10)
1. Выделенная ДНК последовательность, которая кодирует экспрессию гомогенного gр350 протеина.
2. ДНК последовательность по п.1, отличающаяся тем, что содержит нуклеотидную последовательность, в которой, по крайней мере, один нативный нуклеотид, кодирующий серин в положении 501 на фиг.1, заменен ненативным нуклеотидом, и в которой, по крайней мере, один нативный нуклеотид, кодирующий глицин в положении 698, заменен ненативным нуклеотидом.
3. ДНК последовательность по п. 1, отличающаяся тем, что указанный гомогенный gр350 протеин дополнительно отличается тем, что кодирует аминокислотную последовательность, выбранную из группы, состоящей из: (а) аминокислот 19-862 на фиг. 1, (b) аминокислот 1-862 на фиг.1, (с) аминокислот 19-862 и аминокислот 882-907 на фиг. 1, (d) аминокислот 1-862 и аминокислот 882-907 на фиг. 1, (е) аминокислот 1-907, где нуклеотиды, кодирующие, по крайней мере, 8 аминокислот в трансмембранном участке, подверглись делеции.
4. Вектор, содержащий ДНК последовательность по п. 1, 2 или 3.
5. Клетка хозяина, трансформированная ДНК последовательностью по п. 1, 2 или 3, оперативно связанной с последовательностью, контролирующей экспрессию, способной управлять репликацией и экспрессией указанной ДНК последовательности.
6. Способ получения гомогенного gр350 протеина, включающий культивирование клеток хозяина по п. 5 в подходящей культуральной среде, и выделение указанного гомогенного gр350 протеина из указанных клеток.
7. Гомогенный протеин gр350, полученный способом по п. 6.
8. Гомогенный gр350 протеин, отличающийся тем, что в нем один или более из нативных олигонуклеотидов, кодирующих донорный сплайсинговый сайт и акцепторный сплайсинговый сайт, заменен замещающим нуклеотидом (нуклеотидами) отличным от указанного нативного нуклеотида (нуклеотидов), который сохраняет аминокислотную последовательность указанного донорного и акцепторного сайтов.
9. Фармацевтическая композиция, отличающаяся тем, что включает гомогенный gр350 протеин по п.7 или 8 в смеси с фармацевтически приемлемым носителем.
10. Применение гомогенного gр350 протеина для получения фармацевтической композиции, пригодной для профилактического лечения EBV-связанных заболеваний или состояний.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22929194A | 1994-04-18 | 1994-04-18 | |
| US08/229,291 | 1994-04-18 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU96122169A true RU96122169A (ru) | 2000-02-20 |
| RU2178807C2 RU2178807C2 (ru) | 2002-01-27 |
Family
ID=22860582
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU96122169/13A RU2178807C2 (ru) | 1994-04-18 | 1995-04-13 | ВЫДЕЛЕННАЯ ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК, ВЕКТОР, СПОСОБ ПОЛУЧЕНИЯ ГОМОГЕННОГО БЕЛКА gp350, ГОМОГЕННЫЙ БЕЛОК gp350, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ЛЕЧЕНИЯ ЕВV-СВЯЗАННОГО ЗАБОЛЕВАНИЯ ИЛИ СОСТОЯНИЯ |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US6054130A (ru) |
| EP (1) | EP0769056B1 (ru) |
| JP (4) | JP3447743B2 (ru) |
| KR (1) | KR100380953B1 (ru) |
| CN (2) | CN1118573C (ru) |
| AT (1) | ATE210184T1 (ru) |
| AU (1) | AU707837B2 (ru) |
| BR (1) | BR9507473A (ru) |
| CA (1) | CA2187908C (ru) |
| CZ (1) | CZ292283B6 (ru) |
| DE (1) | DE69524415T2 (ru) |
| DK (1) | DK0769056T3 (ru) |
| ES (1) | ES2170144T3 (ru) |
| FI (2) | FI118224B (ru) |
| HU (1) | HU221647B1 (ru) |
| LV (1) | LV11803B (ru) |
| MY (1) | MY114769A (ru) |
| NO (1) | NO319382B1 (ru) |
| PL (1) | PL181881B1 (ru) |
| PT (1) | PT769056E (ru) |
| RU (1) | RU2178807C2 (ru) |
| SK (1) | SK283446B6 (ru) |
| TW (1) | TW496897B (ru) |
| UA (1) | UA47403C2 (ru) |
| WO (1) | WO1995028488A1 (ru) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY114769A (en) | 1994-04-18 | 2003-01-31 | Aviron Inc | Non-splicing variants of gp350/220 |
| US6692749B1 (en) * | 1994-04-18 | 2004-02-17 | Medimmune Vaccines, Inc. | Non-splicing variants of gp350/220 |
| AU2582897A (en) * | 1996-03-15 | 1997-10-01 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation |
| AUPO784197A0 (en) * | 1997-07-10 | 1997-08-07 | Csl Limited | Treatment of nasopharyngeal carcinoma |
| WO1999029848A1 (en) * | 1997-12-05 | 1999-06-17 | The Immune Response Corporation | Novel vectors and genes exhibiting increased expression |
| CA2331258C (en) * | 1998-06-12 | 2011-09-20 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Enhancement of b cell activation and immunoglobulin secretion by co-stimulation of receptors for antigen and ebv gp350/220 |
| GB0210682D0 (en) * | 2002-05-09 | 2002-06-19 | Glaxosmithkline Biolog Sa | Novel use |
| ITMI20031942A1 (it) * | 2003-10-09 | 2005-04-10 | Indena Spa | Dna codificante p185^neu e suoi usi terapeutici |
| ITMI20041965A1 (it) * | 2004-10-15 | 2005-01-15 | Augusto Amici | "dna codificante forme tronche e chimeriche della proteina p185neu e suoi usi terapeutici" |
| MY159370A (en) * | 2004-10-20 | 2016-12-30 | Coley Pharm Group Inc | Semi-soft-class immunostimulatory oligonucleotides |
| WO2010135514A2 (en) * | 2009-05-22 | 2010-11-25 | Intelligent Medical Devices, Inc. | Optimized probes and primers and methods of using same for the detection, screening, quantitation, isolation and sequencing of cytomegalovirus and epstein-barr virus |
| US10461635B1 (en) * | 2018-05-15 | 2019-10-29 | Analog Devices Global Unlimited Company | Low VIN high efficiency chargepump |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3069310D1 (en) * | 1980-11-03 | 1984-10-31 | Itt Ind Gmbh Deutsche | Binary mos ripple carry parallel adder/subtractor and appropriate adding/subtracting stage |
| US4707358A (en) * | 1984-01-30 | 1987-11-17 | The University Of Chicago | Vaccine against Epstein-Barr Virus |
| US5171568A (en) * | 1984-04-06 | 1992-12-15 | Chiron Corporation | Recombinant herpes simplex gb-gd vaccine |
| US5244792A (en) * | 1984-04-06 | 1993-09-14 | Chiron Corporation | Expression of recombinant glyoprotein B from herpes simplex virus |
| EP0173254B1 (en) * | 1984-08-23 | 1991-07-24 | Hans Joachim Wolf | Dna sequences of the ebv genome, recombinant dna molecules, processes for producing ebv-related antigens, diagnostic compositions and pharmaceutical compositions containing said antigens |
| EP0312164A1 (en) * | 1987-10-16 | 1989-04-19 | Merck & Co. Inc. | Purification of recombinant epstein-barr virus antigens from vero cells, yeast cells or L cells |
| CA2090295A1 (en) * | 1992-02-03 | 1993-08-04 | Anthony B. Nesburn | Process for the expression of herpes simplex virus type 1 glycoprotein e and methods of use |
| WO1993019092A1 (fr) * | 1992-03-19 | 1993-09-30 | Centre National De La Recherche Scientifique | Adenovirus recombinants defectifs exprimant des proteines caracteristiques du virus epstein-barr |
| US5474914A (en) * | 1992-07-29 | 1995-12-12 | Chiron Corporation | Method of producing secreted CMV glycoprotein H |
| WO1994020138A1 (en) * | 1993-03-12 | 1994-09-15 | Theratech, Inc. | Recombinant epstein-barr virus protein and its use in vaccine |
| MY114769A (en) | 1994-04-18 | 2003-01-31 | Aviron Inc | Non-splicing variants of gp350/220 |
-
1995
- 1995-04-06 MY MYPI95000884A patent/MY114769A/en unknown
- 1995-04-13 DK DK95916984T patent/DK0769056T3/da active
- 1995-04-13 DE DE69524415T patent/DE69524415T2/de not_active Expired - Lifetime
- 1995-04-13 HU HU9602894A patent/HU221647B1/hu not_active IP Right Cessation
- 1995-04-13 CN CN95193673A patent/CN1118573C/zh not_active Expired - Lifetime
- 1995-04-13 CZ CZ19963054A patent/CZ292283B6/cs not_active IP Right Cessation
- 1995-04-13 PT PT95916984T patent/PT769056E/pt unknown
- 1995-04-13 EP EP95916984A patent/EP0769056B1/en not_active Expired - Lifetime
- 1995-04-13 ES ES95916984T patent/ES2170144T3/es not_active Expired - Lifetime
- 1995-04-13 BR BR9507473A patent/BR9507473A/pt not_active IP Right Cessation
- 1995-04-13 AT AT95916984T patent/ATE210184T1/de active
- 1995-04-13 CN CNB031454984A patent/CN100415895C/zh not_active Expired - Lifetime
- 1995-04-13 JP JP52710995A patent/JP3447743B2/ja not_active Expired - Lifetime
- 1995-04-13 PL PL95316941A patent/PL181881B1/pl not_active IP Right Cessation
- 1995-04-13 WO PCT/US1995/004611 patent/WO1995028488A1/en not_active Ceased
- 1995-04-13 SK SK1343-96A patent/SK283446B6/sk not_active IP Right Cessation
- 1995-04-13 AU AU23838/95A patent/AU707837B2/en not_active Expired
- 1995-04-13 UA UA96114355A patent/UA47403C2/ru unknown
- 1995-04-13 RU RU96122169/13A patent/RU2178807C2/ru not_active IP Right Cessation
- 1995-04-13 KR KR1019960705822A patent/KR100380953B1/ko not_active Expired - Fee Related
- 1995-04-13 CA CA002187908A patent/CA2187908C/en not_active Expired - Lifetime
- 1995-09-13 TW TW084109561A patent/TW496897B/zh not_active IP Right Cessation
-
1996
- 1996-10-18 FI FI964186A patent/FI118224B/fi not_active IP Right Cessation
- 1996-10-18 NO NO19964431A patent/NO319382B1/no not_active IP Right Cessation
- 1996-11-12 LV LVP-96-430A patent/LV11803B/en unknown
-
1997
- 1997-01-15 US US08/783,774 patent/US6054130A/en not_active Expired - Lifetime
- 1997-08-25 US US08/917,320 patent/US5824508A/en not_active Expired - Lifetime
-
2000
- 2000-04-24 US US09/556,706 patent/US6458364B1/en not_active Expired - Lifetime
-
2003
- 2003-02-26 JP JP2003049908A patent/JP2003230396A/ja not_active Withdrawn
-
2004
- 2004-05-19 JP JP2004149099A patent/JP4317786B2/ja not_active Expired - Lifetime
-
2005
- 2005-06-15 JP JP2005175699A patent/JP2005333990A/ja active Pending
-
2007
- 2007-05-10 FI FI20075338A patent/FI20075338L/fi not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Doorbar et al. | Identification of the human papilloma virus‐1a E4 gene products. | |
| RU96122169A (ru) | Нон-сплайсинговые варианты gp350/220 | |
| DK257984A (da) | Fremgangsmaade til fremstilling af en rekombinant baculovirus-udtrykkelsesvektor | |
| EP0279582A3 (en) | Dna sequences to target proteins to the mammary gland for efficient secretion | |
| AU779461C (en) | Osteoprotegerin binding proteins and receptors | |
| IL173399A0 (en) | Circular dna molecule with conditional origin of replication which contains nucleic acid of interest and selection marker but does not encode its replication initiation protein, method for preparing the same and use thereof in gene therapy | |
| AU6964191A (en) | Particle-mediated transformation of animal tissue cells | |
| WO1999029871A3 (fr) | Sequences de circovirus associe a la maladie de l'amaigrissement du porcelet (map) | |
| EA200100670A1 (ru) | СПОСОБ ВЫСОКОПРОДУКТИВНОЙ ЭКСПРЕССИИ АКТИВНЫХ ХИМЕРНЫХ БЕЛКОВ РЕЦЕПТОРА ЛИМФОТОКСИНА-b; И ИММУНОГЛОБУЛИНА И ИХ ВЫДЕЛЕНИЕ | |
| AU5020296A (en) | C-C chemokine receptor 3: CKR-3 or EOS-l2 | |
| WO2001039797A3 (en) | Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant rna-virus | |
| AU7284287A (en) | Recombinant vaccinia virus expressing human retrovirus gene | |
| WO2000034474A3 (en) | Growth factor homolog zvegf3 | |
| Milhausen et al. | Caulobacter flagellin mRNA segregates asymmetrically at cell division | |
| CA2207815A1 (en) | Modulators of the function of fas/apo1 receptors | |
| EP0111814A3 (en) | The cloning and expression of nucleotide sequences encoding bovine growth hormone | |
| AU657698B2 (en) | Method for modifying the cell, tissue or host tropism of a microorganism; recombinant microorganisms obtained in this way and use thereof in medicine and veterinary medicine | |
| KR920004571A (ko) | 헤파린 결합 향신경성 인자(hbnf)를 암호하는 유전자, 이를 포함하는 발현 벡터 및 숙주 세포, 및 hbnf의 생성 방법 및 사용방법 | |
| WO1997007135A3 (en) | Binding of osteogenic protein-i (op-1) and analogs thereof to the cell surface receptor alk-1 and analogs thereof | |
| KR910006483A (ko) | 재조합 아프로티닌 변이체, 균질하게 프로세싱된 아프로티닌 변이체의 미생물을 이용한 유전공학적 제조 방법 및 그의 치료 용도 | |
| CN100415895C (zh) | gp350/220的非剪接变异体 | |
| AU605155B2 (en) | A structural phosphoprotein (PP 15) of human cytomegalovirus, and the preparation and use thereof | |
| KR880002894A (ko) | 주혈흡충증왁진으로 사용되는 단백질과 dna 시퀀스 | |
| CA2191063A1 (en) | Dna encoding glutamate gated chloride channels | |
| EP0811685A3 (en) | Human platelet-derived growth factor receptors |